Jacob Thaysen
CEO
BS
Blue Savant AI
Shutdownbluesavant.net
Website unreachable since Oct 26, 2026
BlueSavant AI utilizes a proprietary machine learning model to analyze genetic expressions from standard blood samples, achieving over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months. This early detection addresses the significant delay in ASD diagnosis, which often occurs after the critical intervention window has passed.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for diagnosing Autism Spectrum Disorder (ASD) rely on behavioral assessments that are often subjective and can only be administered after a child has reached a certain developmental stage. This leads to significant delays in diagnosis, with most children in the US not being diagnosed until after the age of 4, missing critical early intervention opportunities. The lack of objective, early diagnostic tools contributes to the rising societal costs associated with ASD.
Solution
BlueSavant AI offers an early detection solution for ASD through a standard blood test analyzed with a proprietary machine learning model. By analyzing genetic expressions, the test can identify ASD in children as young as 18 months with over 90% precision. This early identification enables timely behavioral interventions, leading to improved outcomes for children with ASD, including enhancements in IQ, verbal communication, and social abilities. The technology provides an objective measure that overcomes the limitations of traditional behavioral assessments, allowing for earlier diagnosis and intervention.
Target Audience
The primary target audience includes pediatricians, neurologists, and other healthcare providers involved in early childhood development, as well as parents seeking early and accurate ASD diagnosis for their children.
Features
- Analyzes genetic expressions from standard blood samples using a proprietary machine learning model.
- Achieves over 90% precision in identifying Autism Spectrum Disorder (ASD) in children as young as 18 months.
- Provides an objective measure for ASD diagnosis, reducing reliance on subjective behavioral assessments.